Nucleobindin 1 caps human islet amyloid polypeptide protofibrils to prevent amyloid fibril formation

Journal of Molecular Biology

Volumn 421, Issue 2-3, 2012, Pages 378-389

  Gupta, Ruchi ^a   Kapoor, Neeraj ^a   Raleigh, Daniel P ^b   Sakmar, Thomas P ^a  

^a ROCKEFELLER UNIVERSITY   (United States)

^b STONY BROOK UNIVERSITY   (United States)

Author keywords

amylin; amyloid; islet amyloid polypeptide; nucleobindin 1; type 2 diabetes mellitus

Indexed keywords

AMYLIN; AMYLOID; CALCIUM BINDING PROTEIN; CALCIUM ION; NUCLEOBINDIN 1; UNCLASSIFIED DRUG;

ARTICLE; ATOMIC FORCE MICROSCOPY; CONTROLLED STUDY; FIBER; GEL PERMEATION CHROMATOGRAPHY; HUMAN; LIGHT SCATTERING; MOLECULAR SIZE; MOLECULAR STABILITY; PRIORITY JOURNAL; PROTEIN AGGREGATION; PROTEIN ANALYSIS; PROTEIN BINDING; PROTEIN FUNCTION; PROTOFIBRIL; SCANNING TRANSMISSION ELECTRON MICROSCOPY;

EID: 84863980717     PISSN: 00222836     EISSN: 10898638     Source Type: Journal    
DOI: 10.1016/j.jmb.2012.04.017     Document Type: Article

References (35)

1. Chiti F., and Dobson C.M. Protein misfolding, functional amyloid, and human disease Annu. Rev. Biochem. 75 2006 333 366
2. Caughey B., and Lansbury P.T. Protofibrils, pores, fibrils, and neurodegeneration: separating the responsible protein aggregates from the innocent bystanders Annu. Rev. Neurosci. 26 2003 267 298
3. Selkoe D.J. Cell biology of protein misfolding: the examples of Alzheimer's and Parkinson's diseases Nat. Cell. Biol. 6 2004 1054 1061
4. Halfmann R., Alberti S., and Lindquist S. Prions, protein homeostasis, and phenotypic diversity Trends Cell. Biol. 20 2010 125 133
5. Chen S., Ferrone F.A., and Wetzel R. Huntington's disease age-of-onset linked to polyglutamine aggregation nucleation Proc. Natl Acad. Sci. USA 99 2002 11884 11889
6. Antzutkin O.N., Leapman R.D., Balbach J.J., and Tycko R. Supramolecular structural constraints on Alzheimer's beta-amyloid fibrils from electron microscopy and solid-state nuclear magnetic resonance Biochemistry 41 2002 15436 15450
7. Luca S., Yau W.M., Leapman R., and Tycko R. Peptide conformation and supramolecular organization in amylin fibrils: constraints from solid-state NMR Biochemistry 46 2007 13505 13522
8. Kayed R., Head E., Thompson J.L., McIntire T.M., Milton S.C., Cotman C.W., and Glabe C.G. Common structure of soluble amyloid oligomers implies common mechanism of pathogenesis Science 300 2003 486 489
9. Lorenzo A., Razzaboni B., Weir G.C., and Yankner B.A. Pancreatic islet cell toxicity of amylin associated with type-2 diabetes mellitus Nature 368 1994 756 760
10. Enoki S., Mitsukawa T., Takemura J., Nakazato M., Aburaya J., Toshimori H., and Matsukara S. Plasma islet amyloid polypeptide levels in obesity, impaired glucose tolerance and non-insulin-dependent diabetes mellitus Diabetes Res. Clin. Pract. 15 1992 97 102
11. Kahn S.E., Andrikopoulos S., and Verchere C.B. Islet amyloid: a long-recognized but underappreciated pathological feature of type 2 diabetes Diabetes 48 1999 241 253
12. Wookey P.J., Lutz T.A., and Andrikopoulos S. Amylin in the periphery II: an updated mini-review TheScientificWorldJournal 6 2006 1642 1655
13. Clark A., and Nilsson M.R. Islet amyloid: a complication of islet dysfunction or an aetiological factor in Type 2 diabetes? Diabetologia 47 2004 157 169
14. Yan L.M., Tatarek-Nossol M., Velkova A., Kazantzis A., and Kapurniotu A. Design of a mimic of nonamyloidogenic and bioactive human islet amyloid polypeptide (IAPP) as nanomolar affinity inhibitor of IAPP cytotoxic fibrillogenesis Proc. Natl Acad. Sci. USA 103 2006 2046 2051
15. Moriarty D.F., and Raleigh D.P. Effects of sequential proline substitutions on amyloid formation by human amylin20-29 Biochemistry 38 1999 1811 1818
16. Mishra R., Bulic B., Sellin D., Jha S., Waldmann H., and Winter R. Small-molecule inhibitors of islet amyloid polypeptide fibril formation Angew. Chem., Int. Ed. Engl. 47 2008 4679 4682
17. Meng F., Abedini A., Plesner A., Middleton C.T., Potter K.J., and Zanni M.T. The sulfated triphenyl methane derivative acid fuchsin is a potent inhibitor of amyloid formation by human islet amyloid polypeptide and protects against the toxic effects of amyloid formation J. Mol. Biol. 400 2010 555 566
18. Meng F., Abedini A., Plesner A., Verchere C.B., and Raleigh D.P. The flavanol (-)-epigallocatechin 3-gallate inhibits amyloid formation by islet amyloid polypeptide, disaggregates amyloid fibrils, and protects cultured cells against IAPP-induced toxicity Biochemistry 49 2010 8127 8133
19. Saraogi I., Hebda J.A., Becerril J., Estroff L.A., Miranker A.D., and Hamilton A.D. Synthetic alpha-helix mimetics as agonists and antagonists of islet amyloid polypeptide aggregation Angew. Chem., Int. Ed. Engl. 49 2010 736 739
20. Gazit E. Mechanisms of amyloid fibril self-assembly and inhibition. Model short peptides as a key research tool FEBS J 272 2005 5971 5978
21. Kawano J., Kotani T., Ogata Y., Ohtaki S., Takechi S., and Nakayama T. CALNUC (nucleobindin) is localized in the Golgi apparatus in insect cells Eur. J. Cell. Biol. 79 2000 208 217
22. Lin P., Fischer T., Lavoie C., Huang H., and Farquhar M.G. Calnuc plays a role in dynamic distribution of Galphai but not Gbeta subunits and modulates ACTH secretion in AtT-20 neuroendocrine secretory cells Mol. Neurodegener. 4 2009 15
23. Kapoor N., Gupta R., Menon S.T., Folta-Stogniew E., Raleigh D.P., and Sakmar T.P. Nucleobindin 1 is a calcium-regulated guanine nucleotide dissociation inhibitor of G{alpha}i1 J. Biol. Chem. 285 2010 31647 31660
24. Goldsbury C., Goldie K., Pellaud J., Seelig J., Frey P., and Muller S.A. Amyloid fibril formation from full-length and fragments of amylin J. Struct. Biol. 130 2000 352 362
25. Hoos M.D., Ahmed M., Smith S.O., and Van Nostrand W.E. Myelin basic protein binds to and inhibits the fibrillar assembly of Abeta42 in vitro Biochemistry 48 2009 4720 4727
26. Srinivasan R., Jones E.M., Liu K., Ghiso J., Marchant R.E., and Zagorski M.G. pH-dependent amyloid and protofibril formation by the ABri peptide of familial British dementia J. Mol. Biol. 333 2003 1003 1023
27. Scheibel T., Kowal A.S., Bloom J.D., and Lindquist S.L. Bidirectional amyloid fiber growth for a yeast prion determinant Curr. Biol. 11 2001 366 369
28. Sievers S.A., Karanicolas J., Chang H.W., Zhao A., Jiang L., and Zirafi O. Structure-based design of non-natural amino-acid inhibitors of amyloid fibril formation Nature 475 2011 96 100
29. Zheng J., Liu C., Sawaya M.R., Vadla B., Khan S., and Woods R.J. Macrocyclic beta-sheet peptides that inhibit the aggregation of a tau-protein-derived hexapeptide J. Am. Chem. Soc. 133 2011 3144 3157
30. Xue W.F., Homans S.W., and Radford S.E. Systematic analysis of nucleation-dependent polymerization reveals new insights into the mechanism of amyloid self-assembly Proc. Natl Acad. Sci. USA 105 2008 8926 8931
31. Collins S.R., Douglass A., Vale R.D., and Weissman J.S. Mechanism of prion propagation: amyloid growth occurs by monomer addition PLoS Biol. 2 2004 e321
32. Knowles T.P., Waudby C.A., Devlin G.L., Cohen S.I., Aguzzi A., and Vendruscolo M. An analytical solution to the kinetics of breakable filament assembly Science 326 2009 1533 1537
33. Bishop M.F., and Ferrone F.A. Kinetics of nucleation-controlled polymerization. A perturbation treatment for use with a secondary pathway Biophys. J. 46 1984 631 644
34. Folta-Stogniew E., and Williams K. Determination of molecular masses of proteins in solution: implementation of an HPLC size exclusion chromatography and laser light scattering service in a core laboratory J. Biomol. Tech. 10 1999 51 63
35. Koppel D.E. Analysis of macromolecular polydispersity in intensity correlation spectroscopy - method of cumulants J. Chem. Phys. 57 1972 4814